To deliver actionable results that can contribute to a clinically meaningful difference in cancer treatment.
The development of state-of-the-art cancer diagnostics and prognostics.
Our strength is in our people. We believe hard working, dedicated people make a significant difference.
To meet and exceed expectations. Never stand still or accept second best.
From Discovery to Market
About Pacific Edge
Pacific Edge encompasses a diverse range of expertise covering all stages in the product life cycle. Our capabilities include cancer genetics, molecular oncology, bioinformatics, clinical research, technology commercialisation, marketing and sales.Read More
Shareholder reports, key dates and services
Pacific Edge is listed on the NZX Main Board and provides an opportunity to invest into the fast growing cancer diagnostic market. Here you will find all the information you need to know about being a shareholder of Pacific Edge Limited.Read More
Diagnostic and Prognostic Technology
Products by Pacific Edge
Pacific Edge has its innovative bladder cancer diagnostic technology, Cxbladder in the marketplace. We are building a complete suite of Cxbladder products to meet a variety of clinical needs.Read More
News & Events
Latest news updates, announcements and calendar of events.
PEB Applies For Australian Stock Exchange (ASX) Dual Listing
Pacific Edge Limited will today lodge an application with the Australian Stock Exchange (ASX) to dual list as a Foreign Exempt Entity. Subject to the ASX accepting the application, PEB expects to be dual-listed on the ASX by the end of September 2021. [read more]Read More
Sign up to receive email notification of news and announcements from Pacific Edge.Subscribe Here